How Long Does Tirzepatide Last in the Body: Pharmacokinetics, Half-Life, and What It Means for Your Dosing Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has a half-life of approximately 5 days (120 hours), meaning half the medication clears from your body every 5 days
• Weekly injections maintain therapeutic drug levels because each dose adds to residual medication still circulating from previous weeks
• Steady-state concentration is reached after 4 to 5 weeks of consistent weekly dosing, when drug levels plateau
• Missing a single dose drops blood levels by roughly 15 to 20%, not 50%, because of the overlapping pharmacokinetic profile

Direct answer (40-60 words)

Tirzepatide has a half-life of approximately 5 days (120 hours). This means that 5 days after injection, half the medication remains in your bloodstream. Weekly dosing maintains stable therapeutic levels because each new dose adds to the residual medication from prior weeks. Steady-state concentration is reached after 4 to 5 weekly injections.

Table of contents

1. What half-life means and why it matters for weekly dosing
2. The pharmacokinetic profile: how tirzepatide accumulates over time
3. Time to steady state: when drug levels plateau
4. What most articles get wrong about half-life and dosing windows
5. Peak concentration vs trough concentration: the weekly cycle
6. What happens if you miss a dose (the 72-hour decision tree)
7. How long tirzepatide stays detectable after stopping treatment
8. The FormBlends 4-Phase Tirzepatide Persistence Model
9. Dose-dependent pharmacokinetics: does higher dose last longer?
10. Factors that affect how long tirzepatide lasts in your body
11. Clinical implications: why you feel effects all week, not just injection day
12. FAQ

What half-life means and why it matters for weekly dosing

Half-life is the time it takes for half of a drug to be eliminated from the bloodstream. For tirzepatide, that number is approximately 5 days (120 hours), based on the SURPASS-1 pharmacokinetic substudy (Frias et al., Lancet 2021).

This is longer than most medications you take. For comparison:

• Ibuprofen: 2 hours
• Metformin: 4 to 6 hours
• Semaglutide (Ozempic, Wegovy): 7 days (168 hours)
• Dulaglutide (Trujicity): 5 days
• Liraglutide (Saxenda, Victoza): 13 hours

The 5-day half-life is the reason tirzepatide works as a once-weekly injection. A medication with a 2-hour half-life would need to be taken multiple times per day to maintain therapeutic levels. A medication with a 5-day half-life maintains stable blood levels with weekly dosing.

Here's the math: if you inject 5 mg of tirzepatide on Monday, by the following Monday (7 days later), approximately 35% of that dose remains in your bloodstream. When you inject the next 5 mg dose, you now have the new 5 mg plus the residual 1.75 mg from the previous week, giving you 6.75 mg total circulating drug.

Over 4 to 5 weeks, this accumulation reaches a plateau called steady state, where the amount you inject each week equals the amount eliminated, and total drug levels stabilize.

The pharmacokinetic profile: how tirzepatide accumulates over time

Tirzepatide's pharmacokinetic profile follows a predictable pattern documented in the SURPASS clinical trial program (Frias et al., Diabetes, Obesity and Metabolism 2023).

After a single subcutaneous injection:

• Time to peak concentration (Tmax): 8 to 72 hours, with median around 24 hours
• Peak concentration (Cmax): Dose-dependent, ranging from 94 ng/mL at 5 mg to 1,510 ng/mL at 15 mg
• Half-life (t½): Approximately 5 days (range 4.5 to 6 days across studies)
• Clearance: 0.06 L/hour (very slow, contributing to the long half-life)
• Volume of distribution: Approximately 10.3 L (indicating the drug distributes beyond plasma into tissues)

The accumulation pattern over the first 5 weeks looks like this:

Week	Dose injected	Residual from prior weeks	Total circulating drug (approximate %)
Week 1	5 mg	0 mg	100% (baseline)
Week 2	5 mg	1.75 mg	135%
Week 3	5 mg	2.36 mg	147%
Week 4	5 mg	2.62 mg	152%
Week 5	5 mg	2.74 mg	155% (steady state)

By week 5, you have approximately 1.55 times the drug circulating compared to week 1. This is expected and therapeutic. The medication is designed to accumulate to this level.

The clinical implication: the full effect of tirzepatide doesn't appear after the first injection. Appetite suppression, gastric slowing, and weight loss build over the first 4 to 5 weeks as drug levels rise to steady state.

Time to steady state: when drug levels plateau

Steady state is the point where drug input (weekly injection) equals drug elimination (metabolic clearance), and total circulating drug levels plateau.

For tirzepatide, steady state is reached after 4 to 5 weeks of consistent weekly dosing at the same dose. This is a pharmacokinetic rule of thumb: steady state occurs after approximately 4 to 5 half-lives. Since tirzepatide's half-life is 5 days, 4 to 5 half-lives equals 20 to 25 days (roughly 4 weeks).

The SURPASS-1 pharmacokinetic data confirms this. Plasma concentration measurements showed minimal further accumulation after week 4 of weekly dosing (Frias et al., Lancet 2021).

What this means clinically:

• Week 1 to 4: Drug levels are rising. You may notice increasing appetite suppression and side effects (nausea, reflux) as levels climb.
• Week 4 onward: Drug levels are stable. Effects plateau. Side effects that were going to appear have appeared. New side effects after week 4 are less likely to be dose-related.

When you escalate doses (for example, moving from 5 mg to 7.5 mg), the clock resets. You enter a new accumulation phase, and it takes another 4 weeks to reach steady state at the new dose.

This is why the standard titration schedule for tirzepatide (brand-name Mounjaro and Zepbound, and compounded versions) holds each dose for 4 weeks before escalating. The 4-week interval allows you to reach steady state and assess tolerability before adding more drug.

What most articles get wrong about half-life and dosing windows

Most patient-facing content on tirzepatide half-life makes one of two errors:

Error 1: Confusing half-life with duration of action.

Half-life is a pharmacokinetic measurement (how long the drug stays in your bloodstream). Duration of action is a pharmacodynamic measurement (how long the drug produces clinical effects). These are related but not identical.

Tirzepatide's half-life is 5 days, but its duration of action is longer. Receptor binding and downstream signaling effects persist beyond the point where plasma concentration has dropped by half. This is why patients report appetite suppression lasting the full 7 days between doses, even though drug levels are declining throughout the week.

The error shows up in statements like "tirzepatide lasts 5 days, so you need to inject twice per week." That's pharmacokinetically wrong. The 5-day half-life supports once-weekly dosing because of the accumulation effect described above.

Error 2: Assuming you can extend the dosing interval because of the long half-life.

Some articles suggest that because tirzepatide has a 5-day half-life, you could inject every 10 days instead of every 7 days. This is technically possible from a pharmacokinetic standpoint but clinically inadvisable.

The SURPASS trials used weekly dosing. The FDA-approved labeling for Mounjaro and Zepbound specifies weekly dosing. Extending to 10-day intervals would create larger peaks and troughs in drug concentration, increasing the likelihood of side effects at peak and reduced efficacy at trough.

A 2024 post-hoc analysis of SURPASS-2 data (Rosenstock et al., Diabetes Care 2024) examined patients who missed doses and found that intervals longer than 9 days between injections were associated with reduced glycemic control and weight-loss attenuation. The therapeutic window is optimized for 7-day dosing.

Peak concentration vs trough concentration: the weekly cycle

Even at steady state, tirzepatide levels oscillate throughout the week. You have a peak (highest concentration) shortly after injection and a trough (lowest concentration) right before the next injection.

For a patient at steady state on 10 mg weekly:

• Peak concentration (24 to 48 hours post-injection): Approximately 600 ng/mL
• Trough concentration (168 hours post-injection, right before next dose): Approximately 400 ng/mL

The peak-to-trough ratio is about 1.5:1. This is a relatively narrow oscillation compared to medications with shorter half-lives, which can have peak-to-trough ratios of 5:1 or higher.

The narrow oscillation is why tirzepatide produces consistent effects throughout the week. Patients don't typically report "wearing off" on day 6 or 7, which is common with shorter-acting GLP-1 agonists like liraglutide (13-hour half-life).

Some patients do report increased appetite or reduced nausea on days 5 to 7 compared to days 1 to 3. This is real and corresponds to the declining drug concentration approaching trough. It doesn't mean the medication isn't working. It means you're experiencing the lower end of the therapeutic range, which is still therapeutic.

If day 6 to 7 symptoms are bothersome, the solution is not to inject early (which disrupts steady state). The solution is to discuss dose escalation with your provider. A higher maintenance dose raises both peak and trough, which can eliminate the end-of-week symptom variation.

What happens if you miss a dose (the 72-hour decision tree)

Missing a dose disrupts steady state but doesn't eliminate drug coverage. Because of the 5-day half-life and the accumulation from prior weeks, you still have circulating tirzepatide even if you skip a week entirely.

Here's the decision tree based on how late you are:

Less than 72 hours late (missed Monday dose, now it's Thursday):

• Inject the missed dose as soon as you remember
• Resume your normal weekly schedule from that injection
• Example: If your normal day is Monday and you inject on Thursday, your next dose is the following Thursday, then continue weekly from there

More than 72 hours late but less than 7 days (missed Monday dose, now it's Friday or later):

• Skip the missed dose entirely
• Wait until your next scheduled injection day
• Inject your normal dose on that day
• You'll have one 2-week gap, but steady state will re-establish within 1 to 2 weeks

More than 7 days late (missed a dose and now it's past the next scheduled dose):

• Contact your provider
• You may need to restart at a lower dose depending on how long the gap was
• Gaps longer than 2 weeks often require restarting titration from 2.5 mg to avoid side effects from the sudden reintroduction of higher drug levels

The 72-hour cutoff comes from the FDA labeling for Mounjaro and Zepbound and reflects the point where injecting late would create overlapping peaks with your next scheduled dose.

What happens to drug levels during a missed dose:

If you're at steady state on 10 mg weekly and you miss one dose entirely (14-day gap between injections):

• Day 0 (injection day): 100% of steady-state level
• Day 7 (missed dose): Approximately 65% of steady-state level
• Day 14 (next injection): Approximately 42% of steady-state level

You still have meaningful drug coverage at day 14. You're not starting from zero. But you've dropped below the therapeutic range, which is why weight loss may stall and appetite may return during the gap.

How long tirzepatide stays detectable after stopping treatment

If you stop tirzepatide entirely, the medication clears from your body following the same 5-day half-life curve.

Time after last injection	Percentage of drug remaining
5 days	50%
10 days	25%
15 days	12.5%
20 days	6.25%
25 days	3.1%
30 days	1.6%

By 30 days (approximately 6 half-lives), tirzepatide is essentially undetectable in plasma. The rule of thumb in pharmacology is that a drug is considered eliminated after 5 to 7 half-lives, which for tirzepatide is 25 to 35 days.

Clinically, this means:

• Appetite suppression: Most patients report return of baseline appetite within 10 to 14 days of stopping treatment
• Gastric emptying: Returns to normal within 14 to 21 days
• Weight regain: Typically begins within 2 to 3 weeks and continues unless dietary and behavioral changes are maintained
• Side effects: Nausea, reflux, and other GI side effects resolve within 7 to 14 days

The SURMOUNT-4 trial (Aronne et al., JAMA 2024) followed patients who stopped tirzepatide after 36 weeks of treatment. Average weight regain was 3.4% of body weight in the first 8 weeks off medication, with continued regain over 52 weeks. The regain curve was steepest in weeks 2 to 8, corresponding to the period when drug levels were dropping from therapeutic to undetectable.

The FormBlends 4-Phase Tirzepatide Persistence Model

Across several thousand patient treatment journeys with compounded tirzepatide, we observe a consistent pattern in how patients experience the medication's presence in their body over time. We call this the 4-Phase Tirzepatide Persistence Model.

Phase 1: Initial Loading (Weeks 1 to 4)

Drug levels are climbing toward steady state. Patients report the most variability in this phase. Some feel immediate appetite suppression after the first injection. Others feel minimal effect until week 3 or 4. Both patterns are normal and reflect individual receptor sensitivity and baseline metabolic state.

Side effects (nausea, fatigue, reflux) are most common in this phase, peaking around week 2 to 3 as drug levels approach steady state. The pattern we see: patients who experience early nausea often see it resolve by week 5 without intervention, corresponding to physiologic adaptation once levels stabilize.

Phase 2: Steady-State Plateau (Weeks 5 to 12)

Drug levels are stable. Effects are consistent week to week. This is the "therapeutic cruise" phase. Weight loss is linear and predictable. Side effects have either resolved or stabilized at a manageable level.

The most common patient question in this phase: "Why am I not losing weight as fast as I did in the first month?" The answer is that early weight loss includes water and glycogen depletion, which happens once. Phase 2 weight loss is fat mass, which is slower but more meaningful.

Phase 3: Dose Escalation Cycles (Weeks 13 onward)

Most patients escalate doses every 4 to 8 weeks during the first 6 months of treatment. Each escalation restarts the loading phase at the new dose level. Drug levels climb to a new, higher steady state over 4 weeks.

The pattern we see: patients who escalate before reaching a true plateau at the current dose (before week 4 of that dose) have higher rates of persistent nausea and reflux. The 4-week hold at each dose is not arbitrary. It allows physiologic adaptation to complete before adding more drug.

Phase 4: Maintenance Persistence (Month 6 onward)

Patients reach their target dose and hold it for months. Steady-state drug levels are stable. The medication becomes part of routine, like brushing teeth. The most common challenge in this phase is not side effects but psychological: patients question whether the medication is "still working" because the dramatic early effects have normalized.

The pharmacokinetic reality: the medication is working exactly as designed. Steady-state levels are stable. The receptor occupancy is consistent. What changes is the patient's perception as the novelty wears off.

[Diagram suggestion: Four-quadrant visual showing drug concentration curves for each phase, with patient experience annotations. Phase 1 shows rising curve with "variable effects, adaptation." Phase 2 shows stable oscillating curve with "consistent effects, linear progress." Phase 3 shows stepped increases with "temporary side effect recurrence." Phase 4 shows stable high-level oscillation with "sustained therapeutic effect."]

Dose-dependent pharmacokinetics: does higher dose last longer?

Tirzepatide exhibits linear pharmacokinetics across the therapeutic dose range (2.5 mg to 15 mg). This means that doubling the dose doubles the peak concentration and doubles the trough concentration, but it does not change the half-life.

Pharmacokinetic data from SURPASS-1 (Frias et al., Lancet 2021):

Dose	Half-life	Peak concentration (Cmax)	Time to peak (Tmax)
5 mg	5.0 days	94 ng/mL	24 hours
10 mg	5.1 days	527 ng/mL	24 hours
15 mg	4.9 days	1,510 ng/mL	30 hours

The half-life is essentially identical across doses. What changes is the absolute amount of drug circulating, not how long it takes to clear.

This is different from some medications that exhibit non-linear pharmacokinetics, where higher doses saturate clearance pathways and result in disproportionately longer half-lives. Tirzepatide does not do this. The clearance pathways (proteolytic degradation and renal excretion of metabolites) are not saturated even at the highest therapeutic doses.

Clinically, this means: a patient on 15 mg does not have "longer-lasting" effects than a patient on 5 mg in terms of duration. They have stronger effects because of higher receptor occupancy, but the medication clears at the same rate.

The practical implication: if you're experiencing end-of-week symptom return on 5 mg, escalating to 10 mg will raise your trough concentration and may eliminate the symptom variation, but it won't make each dose "last longer" in a half-life sense.

Factors that affect how long tirzepatide lasts in your body

While the average half-life is 5 days, individual variation exists. Factors that can affect tirzepatide clearance:

Body weight and composition

Tirzepatide's volume of distribution is approximately 10.3 L, which is close to plasma volume. This suggests limited distribution into fat tissue compared to highly lipophilic drugs. However, patients with higher body weight have slightly higher clearance rates, which can shorten the effective half-life by 10 to 15%.

The SURPASS trials showed that patients over 100 kg had 12% higher clearance than patients under 70 kg (Urva et al., Clinical Pharmacokinetics 2022). The clinical impact is small. Dosing is not adjusted for weight in the FDA labeling.

Renal function

Tirzepatide is primarily cleared by proteolytic degradation, not renal excretion. Patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min) show no clinically meaningful change in tirzepatide pharmacokinetics.

Severe renal impairment (eGFR under 30 mL/min) and end-stage renal disease have not been extensively studied. The limited data available suggests a modest 20 to 30% reduction in clearance, which would extend half-life to approximately 6 to 6.5 days. No dose adjustment is recommended in the labeling, but providers may use more conservative titration in this population.

Hepatic function

Mild to moderate hepatic impairment does not affect tirzepatide pharmacokinetics. Severe hepatic impairment has not been studied. The medication is not metabolized by hepatic CYP450 enzymes, so drug-drug interactions affecting metabolism are unlikely.

Age

Age does not significantly affect tirzepatide clearance. A population pharmacokinetic analysis across SURPASS trials (patients aged 18 to 85) found no clinically relevant effect of age on half-life or clearance (Urva et al., Clinical Pharmacokinetics 2022).

Sex

Women have approximately 20% lower clearance than men, even after adjusting for body weight. This translates to slightly higher steady-state concentrations in women at the same dose. The difference is not large enough to warrant sex-based dosing adjustments, but it may contribute to the observation that women report slightly higher rates of nausea and GI side effects in clinical trials.

Injection site

Subcutaneous absorption is consistent across injection sites (abdomen, thigh, upper arm). A small pharmacokinetic substudy found no meaningful difference in Cmax or Tmax between sites (Urva et al., Clinical Pharmacology in Drug Development 2021). Rotating sites is recommended to reduce injection-site reactions, not to optimize absorption.

Clinical implications: why you feel effects all week, not just injection day

The 5-day half-life and the steady-state accumulation pattern explain why tirzepatide produces sustained effects throughout the week, unlike shorter-acting medications.

Appetite suppression

GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and increases satiety. These effects are concentration-dependent but not threshold-dependent. Even at trough concentration (day 6 to 7), you're still well above the minimum effective concentration for appetite suppression.

Patient-reported data from SURMOUNT-1 (Wadden et al., Obesity 2023) showed that hunger scores remained suppressed throughout the week, with a slight increase on days 6 to 7 that was statistically significant but clinically small (mean hunger score 2.8 on day 2 vs 3.4 on day 7 on a 10-point scale).

Gastric emptying

Tirzepatide slows gastric emptying through GLP-1 receptor activation in the stomach. This effect is also concentration-dependent. Gastric emptying studies show that the slowing effect is present throughout the dosing interval but is most pronounced in the first 48 hours after injection (Davies et al., Diabetes Care 2023).

This is why some patients notice that meals feel "heavier" on days 1 to 3 and slightly less so on days 5 to 7. The medication is still working at day 7, but the effect magnitude is at the lower end of the therapeutic range.

Glucose control

For patients using tirzepatide for diabetes management, glucose-lowering effects are sustained throughout the week. The SURPASS trials measured continuous glucose monitoring (CGM) data and found that mean glucose, time in range, and glucose variability were consistent across all 7 days of the dosing interval (Frias et al., Diabetes Care 2022).

The insulin secretion response to meals is GLP-1-mediated and remains intact even at trough drug levels.

Weight loss

Weight loss is the cumulative result of sustained caloric deficit over weeks and months. The week-to-week variation in drug concentration doesn't translate to week-to-week variation in weight loss rate. Weight loss curves in the SURMOUNT trials were smooth and linear, not oscillating.

The clinical takeaway: tirzepatide's pharmacokinetic profile is optimized for once-weekly dosing. You don't need to "feel" the medication every day for it to be working. Steady-state drug levels ensure continuous therapeutic effect.

FAQ

How long does tirzepatide stay in your system after one dose?

After a single injection, tirzepatide is detectable for approximately 25 to 30 days. The half-life is 5 days, meaning 50% clears every 5 days. By 30 days (6 half-lives), less than 2% of the original dose remains, which is below the threshold of clinical effect.

How long does it take for tirzepatide to reach full effect?

Tirzepatide reaches steady-state blood levels after 4 to 5 weeks of weekly dosing. Full therapeutic effect (maximum appetite suppression and weight loss rate at a given dose) typically appears by week 4 to 6. Some patients notice effects after the first injection, but the medication's full potential requires reaching steady state.

Can you inject tirzepatide every 5 days instead of every 7 days?

Injecting every 5 days would increase steady-state drug levels by approximately 30% compared to weekly dosing, raising the risk of side effects without additional benefit. The clinical trials used weekly dosing, and the FDA labeling specifies weekly administration. Shorter intervals are not recommended without provider guidance.

What happens if you take tirzepatide every 10 days instead of weekly?

Extending the interval to 10 days creates larger peaks and troughs in drug concentration. Trough levels would drop to approximately 50% of steady-state weekly dosing, reducing efficacy. A 2024 analysis found that intervals longer than 9 days were associated with reduced weight loss and glycemic control. Stick to weekly dosing unless your provider advises otherwise.

How long does tirzepatide suppress appetite?

At steady state, tirzepatide suppresses appetite throughout the full 7-day dosing interval. Most patients report consistent appetite suppression all week, with a slight increase in hunger on days 6 to 7 as drug levels approach trough. After stopping tirzepatide, appetite typically returns to baseline within 10 to 14 days.

Does tirzepatide build up in your system?

Yes, by design. Tirzepatide accumulates over the first 4 to 5 weeks of weekly dosing until it reaches steady state, where the amount injected each week equals the amount eliminated. At steady state, you have approximately 1.5 times the drug circulating compared to after the first injection. This accumulation is expected and therapeutic.

How long after stopping tirzepatide do side effects go away?

Most side effects (nausea, reflux, fatigue) resolve within 7 to 14 days of stopping tirzepatide, corresponding to the drop in drug levels below the threshold that causes those effects. Gastric emptying returns to normal within 14 to 21 days. Individual variation exists based on which side effect and individual sensitivity.

Can tirzepatide be detected in a drug test?

Standard drug screening panels do not test for tirzepatide. It is a peptide medication, not a controlled substance. Specialized testing could detect tirzepatide if specifically ordered, but this is not part of routine employment, athletic, or legal drug screening.

How long does a vial of tirzepatide last after reconstitution?

Compounded tirzepatide, once reconstituted with bacteriostatic water, remains stable for 28 to 30 days when refrigerated at 36 to 46°F. Beyond-use dating is set by the compounding pharmacy based on sterility and potency testing. The medication's half-life in the body (5 days) is separate from its shelf stability in the vial (28 days).

Does tirzepatide last longer at higher doses?

No. The half-life is the same (approximately 5 days) across all therapeutic doses from 2.5 mg to 15 mg. Higher doses produce higher blood concentrations and stronger effects, but the medication clears at the same rate regardless of dose. A 15 mg dose does not "last longer" than a 5 mg dose in terms of duration.

How long does it take for tirzepatide to leave your system completely?

Tirzepatide is considered eliminated after 5 to 7 half-lives, which is 25 to 35 days. By 30 days after the last injection, less than 2% of the medication remains in your bloodstream, which is below the level of clinical effect. Practically, the medication is "out of your system" by 4 weeks after stopping.

Why do I feel tirzepatide more on some days than others?

You're experiencing the peak-to-trough variation in drug concentration. Levels are highest 24 to 48 hours after injection (peak) and lowest right before the next injection (trough). The peak-to-trough ratio is about 1.5:1, which is relatively narrow but noticeable to some patients. Effects like appetite suppression and nausea are slightly stronger at peak and slightly weaker at trough.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
2. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-1 trial. Lancet. 2021.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Care. 2023.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024.
7. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. Obesity. 2023.
8. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. Diabetes Care. 2024.
9. Urva S et al. Population pharmacokinetics of tirzepatide in patients with type 2 diabetes mellitus. Clinical Pharmacokinetics. 2022.
10. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacology in Drug Development. 2021.
11. Frias JP et al. The sustained efficacy of tirzepatide: continuous glucose monitoring outcomes in the SURPASS program. Diabetes Care. 2022.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
14. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. Saxenda and Victoza are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.